相似文献
1
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises.
Ann Transl Med. 2022 May;10(9):501. doi: 10.21037/atm-22-621.
2
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Sci Rep. 2020 Jan 22;10(1):973. doi: 10.1038/s41598-020-58009-3.
3
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.
4
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
Mol Cell Pharmacol. 2023;15(1):1-5.
5
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Ann Pharmacother. 2021 Jul;55(7):921-931. doi: 10.1177/1060028020966548. Epub 2020 Oct 17.
6
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
MAbs. 2019 Aug/Sep;11(6):987-995. doi: 10.1080/19420862.2019.1632115. Epub 2019 Jul 18.
7
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.
8
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Expert Rev Anticancer Ther. 2021 Dec;21(12):1303-1311. doi: 10.1080/14737140.2021.1993065. Epub 2021 Oct 22.
9
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Expert Rev Anticancer Ther. 2019 Aug;19(8):673-679. doi: 10.1080/14737140.2019.1654378. Epub 2019 Aug 19.
10
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Front Oncol. 2020 Feb 12;10:118. doi: 10.3389/fonc.2020.00118. eCollection 2020.
引用本文的文献
1
Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization.
Biomedicines. 2025 May 21;13(5):1266. doi: 10.3390/biomedicines13051266.
2
Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report.
Ther Adv Med Oncol. 2025 Feb 26;17:17588359251322003. doi: 10.1177/17588359251322003. eCollection 2025.
3
Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy.
Int J Mol Sci. 2025 Jan 8;26(2):474. doi: 10.3390/ijms26020474.
4
A Review of Current and Future Antibody Drug Conjugates in Breast Cancer.
Curr Treat Options Oncol. 2024 Dec;25(12):1506-1516. doi: 10.1007/s11864-024-01276-3. Epub 2024 Nov 29.
5
Trop2-targeted therapies in solid tumors: advances and future directions.
Theranostics. 2024 Jun 11;14(9):3674-3692. doi: 10.7150/thno.98178. eCollection 2024.
6
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.
Curr Oncol. 2024 Apr 19;31(4):2316-2327. doi: 10.3390/curroncol31040172.
7
Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
Curr Treat Options Oncol. 2024 Apr;25(4):556-584. doi: 10.1007/s11864-024-01196-2. Epub 2024 Mar 23.
8
Targeting Trop2 in solid tumors: a look into structures and novel epitopes.
Front Immunol. 2023 Dec 20;14:1332489. doi: 10.3389/fimmu.2023.1332489. eCollection 2023.
9
Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies.
Int J Mol Sci. 2023 Jul 13;24(14):11395. doi: 10.3390/ijms241411395.
10
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody.
Cancers (Basel). 2023 Jul 22;15(14):3721. doi: 10.3390/cancers15143721.
本文引用的文献
1
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23.
2
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
Molecules. 2021 Sep 27;26(19):5847. doi: 10.3390/molecules26195847.
3
Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
Ann Transl Med. 2021 Jul;9(14):1113. doi: 10.21037/atm-21-1103.
4
Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer.
Neoplasia. 2021 Sep;23(9):898-911. doi: 10.1016/j.neo.2021.07.002. Epub 2021 Jul 25.
5
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8.
6
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.
J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30.
7
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
8
Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.
Neoplasia. 2021 Apr;23(4):415-428. doi: 10.1016/j.neo.2021.03.006. Epub 2021 Apr 8.
9
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Expert Opin Biol Ther. 2020 Aug;20(8):871-885. doi: 10.1080/14712598.2020.1757067. Epub 2020 May 12.
10
Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
Anal Chem. 2020 Jan 7;92(1):1260-1267. doi: 10.1021/acs.analchem.9b04419. Epub 2019 Dec 9.
Zotero 插件